These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31960728)

  • 21. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
    Natarajan A; Zaman AG; Marshall SM
    Diab Vasc Dis Res; 2008 Jun; 5(2):138-44. PubMed ID: 18537103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.
    Lettino M; Leonardi S; De Maria E; Halvorsen S
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):61-70. PubMed ID: 28618904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.
    Nathan AS; Sen S; Yeh RW
    Expert Opin Drug Saf; 2017 May; 16(5):561-572. PubMed ID: 28387542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials.
    Zaccardi F; Pitocco D; Willeit P; Laukkanen JA
    Atherosclerosis; 2015 Jun; 240(2):439-45. PubMed ID: 25897998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel aspects of antiplatelet therapy in cardiovascular disease.
    Gremmel T; Michelson AD; Frelinger AL; Bhatt DL
    Res Pract Thromb Haemost; 2018 Jul; 2(3):439-449. PubMed ID: 30046748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current antiplatelet agents, new inhibitors and therapeutic targets].
    El Alaoui MZ; Guy A; Khalki L; Limami Y; Benomar A; Zaid N; Cherrah Y; Mekhfi H; Cadi R; Zaid Y
    Med Sci (Paris); 2020 Apr; 36(4):348-357. PubMed ID: 32356711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
    Bhandari B; Mehta B
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of platelets and antiplatelet therapy in cardiovascular disease.
    Ueno M; Kodali M; Tello-Montoliu A; Angiolillo DJ
    J Atheroscler Thromb; 2011; 18(6):431-42. PubMed ID: 21427504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
    Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease.
    Connor DE; Ly K; Aslam A; Boland J; Low J; Jarvis S; Muller DW; Joseph JE
    Platelets; 2016 Dec; 27(8):805-811. PubMed ID: 27310292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of antiplatelet agents in sepsis: a glimpse into the future.
    Akinosoglou K; Alexopoulos D
    Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiplatelet agents.
    Varon D; Spectre G
    Hematology Am Soc Hematol Educ Program; 2009; ():267-72. PubMed ID: 20008209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New perspectives in antiplatelet therapy.
    Tello-Montoliu A; Jover E; Rivera J; Valdés M; Angiolillo DJ; Marín F
    Curr Med Chem; 2012; 19(3):406-27. PubMed ID: 22335515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The progress in the research of antiplatelet agents (1995-2017).
    Benimana O; Zhao L; Kong Y; Li Z; Xie Z
    Future Med Chem; 2017 Jun; 9(10):1087-1110. PubMed ID: 28632424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.
    Montalescot G
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):371-80. PubMed ID: 20566574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.